A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
Fatima Karzai(National Institutes of Health), William L. Dahut(National Cancer Institute), Jane B. Trepel(National Institutes of Health), Amy Hankin(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Keith Killian(National Institutes of Health), James L. Gulley(National Cancer Institute), Anna Couvillon(National Institutes of Health), Jung Min Lee(Kyung Hee University), Monique Williams(National Institutes of Health), Paul S. Meltzer(National Cancer Institute), Helen Owens(National Institutes of Health), Lisa M. Cordes(National Institutes of Health Clinical Center)
Cited by 50
Related Papers
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing
|Nature Communications|2018|964
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711